Barrett's esophagus and its progression to adenocarcinoma

Carlo Maley, Anil K. Rustgi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Barrett's esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EA). Therefore, the presence of BE identifies a high-risk group of patients who may be followed-up for early detection of EA and treated to reduce the risk for its progression. The initiating event for BE is unknown, although it is associated with chronic gastric reflux. Many of the genetic lesions involved in BE neoplastic progression are known, including loss of CDKN2A (p16) and TP53 (p53) and the development of tetraploidy and aneuploidy. Intensive endoscopic surveillance has been shown to improve survival although it can be difficult to implement in practice. Several exposures may be altered to reduce the risk for progression, including weight, diet, and the use of nonsteroidal anti-inflammatory drugs. However, most of these results should be confirmed in additional cohorts before they are used to change clinical practice.

Original languageEnglish (US)
Pages (from-to)367-374
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number4
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Barrett Esophagus
Adenocarcinoma
Tetraploidy
Aneuploidy
Stomach
Anti-Inflammatory Agents
Diet
Weights and Measures
Survival
Pharmaceutical Preparations

Keywords

  • Aneuploidy
  • Barrett's esophagus
  • CDKN2A
  • Esophageal adenocarcinoma
  • NSAID
  • Obesity
  • TP53

ASJC Scopus subject areas

  • Oncology

Cite this

Barrett's esophagus and its progression to adenocarcinoma. / Maley, Carlo; Rustgi, Anil K.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 4, No. 4, 04.2006, p. 367-374.

Research output: Contribution to journalArticle

@article{a5e4c787bf7741d7b7d748e8cacf1bba,
title = "Barrett's esophagus and its progression to adenocarcinoma",
abstract = "Barrett's esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EA). Therefore, the presence of BE identifies a high-risk group of patients who may be followed-up for early detection of EA and treated to reduce the risk for its progression. The initiating event for BE is unknown, although it is associated with chronic gastric reflux. Many of the genetic lesions involved in BE neoplastic progression are known, including loss of CDKN2A (p16) and TP53 (p53) and the development of tetraploidy and aneuploidy. Intensive endoscopic surveillance has been shown to improve survival although it can be difficult to implement in practice. Several exposures may be altered to reduce the risk for progression, including weight, diet, and the use of nonsteroidal anti-inflammatory drugs. However, most of these results should be confirmed in additional cohorts before they are used to change clinical practice.",
keywords = "Aneuploidy, Barrett's esophagus, CDKN2A, Esophageal adenocarcinoma, NSAID, Obesity, TP53",
author = "Carlo Maley and Rustgi, {Anil K.}",
year = "2006",
month = "4",
language = "English (US)",
volume = "4",
pages = "367--374",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Barrett's esophagus and its progression to adenocarcinoma

AU - Maley, Carlo

AU - Rustgi, Anil K.

PY - 2006/4

Y1 - 2006/4

N2 - Barrett's esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EA). Therefore, the presence of BE identifies a high-risk group of patients who may be followed-up for early detection of EA and treated to reduce the risk for its progression. The initiating event for BE is unknown, although it is associated with chronic gastric reflux. Many of the genetic lesions involved in BE neoplastic progression are known, including loss of CDKN2A (p16) and TP53 (p53) and the development of tetraploidy and aneuploidy. Intensive endoscopic surveillance has been shown to improve survival although it can be difficult to implement in practice. Several exposures may be altered to reduce the risk for progression, including weight, diet, and the use of nonsteroidal anti-inflammatory drugs. However, most of these results should be confirmed in additional cohorts before they are used to change clinical practice.

AB - Barrett's esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EA). Therefore, the presence of BE identifies a high-risk group of patients who may be followed-up for early detection of EA and treated to reduce the risk for its progression. The initiating event for BE is unknown, although it is associated with chronic gastric reflux. Many of the genetic lesions involved in BE neoplastic progression are known, including loss of CDKN2A (p16) and TP53 (p53) and the development of tetraploidy and aneuploidy. Intensive endoscopic surveillance has been shown to improve survival although it can be difficult to implement in practice. Several exposures may be altered to reduce the risk for progression, including weight, diet, and the use of nonsteroidal anti-inflammatory drugs. However, most of these results should be confirmed in additional cohorts before they are used to change clinical practice.

KW - Aneuploidy

KW - Barrett's esophagus

KW - CDKN2A

KW - Esophageal adenocarcinoma

KW - NSAID

KW - Obesity

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=33747111083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747111083&partnerID=8YFLogxK

M3 - Article

C2 - 16569389

AN - SCOPUS:33747111083

VL - 4

SP - 367

EP - 374

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 4

ER -